Formycon AG (ETR:FYB)

Market Cap	399.41M -1.0%
Revenue (ttm)	52.28M -13.9%
Net Income	-56.90M
EPS	-3.22
Shares Out	17.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,578
Open	21.65
Previous Close	21.30
Day's Range	21.35 - 22.70
52-Week Range	15.80 - 31.30
Beta	0.65
Analysts	Buy
Price Target	39.86 (+76.37%)
Earnings Date	May 28, 2026

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 203
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: FYB

Financial Performance

In 2025, Formycon AG's revenue was 44.48 million, a decrease of -36.17% compared to the previous year's 69.67 million. Losses were -64.70 million, -48.52% less than in 2024.